Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2241-2247

  Spila, Antonella ^a   Roselli, Mario ^b   Cosimelli, Maurizio ^a   Ferroni, Patrizia ^c   Cavaliere, Francesco ^a   Arcuri, Raffaella ^a   Tedesco, Manfredo ^a   Carlini, Sandro ^a   D'Alessandro, Roberta ^a   Perri, Pasquale ^a   Casciani, Carlo U ^b   Greiner, John W ^d   Schlom, Jeffrey ^d   Guadagni, Fiorella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CA 19 9; CA 72 4; CEA; Gastric cancer; Post surgical monitoring; Serum markers; Serum markers' half life; Staging; Surgical treatment

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STOMACH CARCINOMA;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 9444272190     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sheer DG, Schlom J, Cooper HL: Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 48: 6811-18, 1998.
2. Katari RS, Fernsten PD, Schlom J: Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res 50: 4885-90, 1990.
3. Colcher D, Horan Hand P, Nuti M, Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U.S.A. 78: 3199-203, 1981.
4. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46: 850-57, 1986.
5. Muraro R, Kuroki D, Wunderlich D, Poole DJ, Colcher D, Thor A. Greiner JW, Simpson JF, Molinolo A, Noguchi P, Schlom J: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein 72 antigen. Cancer Res 48: 4588-96, 1988.
6. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48: 4597-603, 1988.
7. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46: 3118-24, 1986.
8. Molinolo A, Simpson JF, Thor A, Schlom J: Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 50: 1291-98, 1990.
9. Nuti M, Teramoto YA, Mariani-Costantini R, Horan Hand P, Colcher D, Schlom J: A monoclonal antibody (B72.3) defines pattern of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 29: 539-45, 1982.
10. Stramignoni D, Bowen R, Atkinson B, Schlom J: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 31: 543-52, 1983.
11. Thor A. Viglione MJ, Muraro R, Ohuchi N, Schlom J, Gorstein F: Monoclonal antibody B72.3 reactivity with human endometrium: A study of normal and malignant tissues. Int J Gyn Path 6: 235-47, 1987.
12. Wolf RC, D'Emilia JC, Salem RR, DeCoste D, Sears HF, Gottlieb LS Steele GD Jr: Detection of the tumor associated glycoprotein (TAG-72) in premalignant lesions of the colon. J Natl Cancer Inst 81: 1913-17, 1989.
13. Xu M, Real FX, Welt S, Schussler MH, Oettgen HF, Old LJ: Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int J Cancer 44: 985-989, 1989.
14. Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N, Masuda M, Mori S: Comparison of serum assay for TAG-72, CA 19-9. and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 19: 242-248, 1989.
15. Ohuchi N, Gero E, Mori S, Akimoto M, Matoba N, Nishihira T, Hirayama K, Colcher D, Schlom J: Clinical evaluation of CA 72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma. J Tumor Marker Oncol 5: 1-10, 1990.
16. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito MR, Cavaliere R, Colcher D, Greiner JW, Schlom J: Tumor-associated glycoprotein-72 (TAG-72) serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma: A longitudinal study. Cancer 68: 2443-50, 1991.
17. Guadagni F, Roselli M, Ferroni P, Amato T, Colcher D, Greiner JW, Schlom J: Clinical evaluation of the new tumor marker TAG-72. Anticancer Res 11: 1389-1394, 1991.
18. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Tedesco M, Grassi A, Casale V, Cavaliere F, Greiner JW, Schlom J: Clinical evaluation of serum Tumor-Associated Glycoprotein-72 as a novel tumor marker for colorectal cancer patients. J Surg Oncol 2: 16-20, 1991.
19. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Tedesco M, Cavaliere F, Grassi A, Abbolito MR, Greiner JW, Schlom J: TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to CEA in monitoring colorectal cancer patients. Cancer 72: 2098-106, 1993.
20. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, Abbolito MR, Greiner JW, Schlom J: Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, Part I. Dis Colon Rectum 37: S16-S23, 1994.
21. Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, Carlini M, Santoro E, Cavaliere R, Greiner JW, Schlom J: The CA 72-4 assay as a serum marker in the management of gastric carcinoma. Cancer Res 52: 1222-1227, 1992.
22. Gero EJ, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P: The CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma associated antigen in serum of patients. J. Clin Lab Analysis 3: 360-9, 1989.
23. Del Villano BC, Brennan S, Brock P, Bucker C, Liu U, Mc Clure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski VR Jr: Radioimmunomctric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29: 549-552, 1983.
24. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Casaldi V, Cavaliere F, Carlini M, Garofalo A, Rinaldi G, Santoro E, Greiner JW, Schlom J: Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric cancer. Anticancer Res 13: 2409-2414, 1993.
25. Goldenberg DM, Neville AM, Cortes AC, Go VLV, Holyoke ED, Issellbacher D: Carcinoembryonic antigen: its role as a marker in the management of cancer: a National Institutes of Health Consensus Development Conference. Ann Intern Med 94: 407-409, 1987.
26. Sikorska H, Shuster J, Gold P: Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 12: 321-55, 1988.
27. Herlyn M, Sears HF, Steplewski Z, Koprowski H: Monoclonal antibody detection of a circulating tumor-associated antigen. I: Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 2: 135-140, 1982.
28. Ritts RE Jr, Del Villano BC, Go VL, Herberman RB, Klug TL, Zurawski VR Jr: Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer 33: 339-345, 1984.
29. Koga T, Kano T, Souda K, Oka N, Inokuchi K: The clinical usefulness of preoperative CEA determination in gastric cancer. Jap J Surg 17: 342-7, 1987.
30. Sipponen P, and Lindgren J: Sialylated Lewisa determinant CA 19-9 in benign and malignant gastric tissue. Acta Pathol Microbiol Immunol Scand, Sect A 94: 305-311, 1986.
31. Staab HJ, Hournung A, Anderer FA, Kiieninger G: Clinical significance of the circulating tumor-associated antigen CA 19-9 in cancers of the digestive tract. Dtsch Med Wochenschr 109: 1141, 1984.
32. Byrne DJ, Browning MCK, Cuschieri A: CA 72-4: a new tumour marker for gastric cancer. Br J Surg 77: 1010-1013, 1990.
33. Hamazoe R, Macta M, Matsui T, Shibata S, Shiota S, Kaibara N: CA 72-4 compared with carcinoembryonic antigen as a tumor marker for gastric cancer. Eur J Cancer 28A: 1351-54, 1992.
34. Semjonof A, Hamm M, Rathert P: Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 11: 218-220, 1993.